Advertisement

Sex, Drugs, and How to Deal with Criticism: The Case of Flibanserin

  • Anke BueterEmail author
  • Saana Jukola
Chapter
  • 23 Downloads
Part of the Boston Studies in the Philosophy and History of Science book series (BSPS, volume 338)

Abstract

In 2015, the US Food and Drug Administration made the controversial decision to approve flibanserin as the first drug against problems of low female sexual desire. This approval has encountered many criticisms; in particular, it has been condemned as an exemplary instance of medicalization and disease-mongering, as lacking sufficient evidential support, and as targeting a highly problematic diagnosis (Hypoactive Sexual Desire Disorder). In this paper, we review these complaints and show that many of the issues in the flibanserin case stem from a failure to properly deal with criticism. We argue that a principle of uptake of criticism can help preventing bias in research and drug regulation and can be secured by institutional measures.

References

  1. American Psychiatric Association (APA). (1994). Diagnostic and statistical manual of mental disorders (DSM-IV) (4th ed.). Washington, DC: APA.Google Scholar
  2. APA. (2008). Principles for DSM-5 Task Force and Work Group Members. http://web.archive.org/web/20120404114422/http://www.psych.org/MainMenu/Research/DSMIV/DSMV/BOTPrinciples.aspx. Assessed 8 Aug 2016.
  3. APA. (2013). Diagnostic and statistical manual of mental disorders (DSM-5) (5th ed.). Washington, DC: APA.Google Scholar
  4. Balon, R., & Clayton, A. H. (2014). Female sexual interest/arousal disorder: A diagnosis out of thin air. Archives of Sexual Behavior, 43, 1227–1229.CrossRefGoogle Scholar
  5. Basson, R. (2000). The female sexual response: A different model. Journal of Sex and Marital Therapy, 26, 51–64.CrossRefGoogle Scholar
  6. Boehringer Pulls the Plug on “Pink Viagra”. (2010, October 8). https://www.reuters.com/article/us-boehringer-flibanserin/boehringer-pulls-the-plug-on-pink-viagra-idUSTRE6970TN20101008. Accessed 13 Sept 2017.
  7. Bradford, A. (2012). Listening to placebo in clinical trials for female sexual dysfunction. The Journal of Sexual Medicine, 10, 451–459.CrossRefGoogle Scholar
  8. Brotto, L. A. (2010). The DSM diagnostic criteria for hypoactive sexual desire disorder in women. Archives of Sexual Behavior, 39, 221–239.CrossRefGoogle Scholar
  9. Brotto, L. A., et al. (2011). Should sexual desire and arousal disorders in women be merged? A response to DeRogatis, Clayton, Rosen, Sand, and Pyke (2010). Archives of Sexual Behavior, 40, 221–225.CrossRefGoogle Scholar
  10. Brotto, L. (2015). Flibanserin. Archives of Sexual Behavior, 44(8), 2103–2105.Google Scholar
  11. Bueter, A. (2017). Androcentrism, feminism, and pluralism in medicine. Topoi, 36, 521–530.CrossRefGoogle Scholar
  12. Clayton, A. H. (2010). The pathophysiology of hypoactive sexual desire disorder in women. International Journal of Gynecology & Obstetrics, 110, 7–11.CrossRefGoogle Scholar
  13. De Angelis, C., Drazen, J., Frizelle, F., Haug, C., Hoey, J., Horton, R., Kotzin, S., Laine, C., Marusic, A., Overbeke, A., Schroeder, T., Sox, H., & Van Der Weyden, M. (2004). Clinical trial registration. A statement from the International Committee of Medical Journal Editors. New England Journal of Medicine, 35, 1250–1251.CrossRefGoogle Scholar
  14. DeRogatis, L. R., et al. (2011). Should sexual desire and arousal disorders in women be merged? Archives of Sexual Behavior, 40, 217–219.CrossRefGoogle Scholar
  15. DeRogatis, L., Komer, L., Katz, M., & et al. VIOLET Trial investigators. (2012). Treatment of hypoactive sexual desire disorder in premenopausal women: Efficacy of flibanserin in the VIOLET study. The Journal of Sexual Medicine, 9(4), 1074–1085.CrossRefGoogle Scholar
  16. Dreifus, C. (Ed.). (1978). Seizing our bodies: The politics of women’s health. New York: Vintage Books.Google Scholar
  17. Ehrenreich, B., & English, D. (1978). For her own good: 150 years of the experts’ advice to women. New York: Anchor Books.Google Scholar
  18. Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women with Hypoactive Sexual Desire Disorder. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00996164. Accessed 4 Aug 2016.
  19. Forbes, M., Baillie, A., & Schniering, C. (2014). Critical flaws in the female sexual dysfunction index and the international index of erectile dysfunction. The Journal of Sexual Research, 57, 485–491.CrossRefGoogle Scholar
  20. Frühauf, S., et al. (2013). Efficacy of psychological interventions for sexual dysfunction: A systematic review and meta-analysis. Archives of Sexual Behavior, 42, 915–933.CrossRefGoogle Scholar
  21. Gellad, W., Flynn, K., & Alexander, G. (2015). Evaluation of Flibanserin. Science and advocacy at the FDA. JAMA, 314(9), 869–870.CrossRefGoogle Scholar
  22. Graham, C. A. (2010). The DSM diagnostic criteria for female sexual arousal disorder. Archives of Sexual Behavior, 39, 240–255.CrossRefGoogle Scholar
  23. Graham, C. A., Brotto, L. A., & Zucker, K. J. (2014). Response to Balon and Clayton (2014): Female sexual interest/arousal disorder is a diagnosis more on firm ground than thin air. Archives of Sexual Behavior, 43, 1231–1234.CrossRefGoogle Scholar
  24. Howick, J. (2011). Philosophy of evidence-based medicine. Oxford: BMJ Books/Wiley-Blackwell.CrossRefGoogle Scholar
  25. Jaspers, L., Feys, F., Bramer, W., Franco, O., Leusink, P., & Laan, E. (2016). Efficacy and safety of Flibanserin for the treatment of hypoactive sexual desire disorder in women. A systematic review and meta-analysis. JAMA Internal Medicine, 176(4), 453–562.CrossRefGoogle Scholar
  26. Joffe, H. (2015). Division director review. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000SumRedt.pdf. Accessed 6 June 2016.
  27. Jutel, A. (2010). Framing disease: The example of female hypoactive sexual desire disorder. Social Science & Medicine, 70, 1084–1090.CrossRefGoogle Scholar
  28. Katz, M., Derogatis, L., Ackerman, R., & et al. Begonia Trial Investigators. (2013). Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. The Journal of Sexual Research, 10(7), 1807–1815.CrossRefGoogle Scholar
  29. Laumann, E. O., Paik, A., & Rosen, R. C. (1999). Sexual dysfunction in the United States: Prevalence and predictors. JAMA, 281, 537–544.CrossRefGoogle Scholar
  30. Longino, H. (1990). Science as social knowledge: Values and objectivity in scientific inquiry. Princeton: Princeton University Press.Google Scholar
  31. Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2017). Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews, 2, MR000033.  https://doi.org/10.1002/14651858.MR000033.pub3.CrossRefGoogle Scholar
  32. Masters, W. H., & Johnson, V. E. (1966). Human sexual response. Boston: Little, Brown.Google Scholar
  33. McCabe, M. P., & Goldhammer, D. L. (2013). Prevalence of women’s sexual desire problems: What criteria do we use? Archives of Sexual Behavior, 42, 1073–1078.CrossRefGoogle Scholar
  34. McClimans, L. (2013). The role of measurement in establishing evidence. The Journal of Medicine and Philosophy, 38(5), 520–538.CrossRefGoogle Scholar
  35. McClimans, L., & Browne, J. (2011). Choosing a patient-reported outcome measure. Theoretical Medicine and Bioethics, 32, 47–60.CrossRefGoogle Scholar
  36. Meixel, A., Yanchar, E., & Fugh-Berman, A. (2016). Hypoactive sexual desire disorder: Inventing a disease to sell low libido. Journal of Medical Ethics, 41, 859–862.CrossRefGoogle Scholar
  37. Merton, R. K. (1942). The sociology of science: Theoretical and empirical investigations. Chicago: University of Chicago Press.Google Scholar
  38. Moynihan, R. (2005). The marketing of a disease: Female sexual dysfunction. British Medical Journal, 330, 192–194.CrossRefGoogle Scholar
  39. Moynihan, R., & Mintzes, B. (2010). Sex, lies, + pharmaceuticals: How drug companies plan to profit from female sexual dysfunction. Vancouver: Greystone Books.Google Scholar
  40. Park, K., Goldstein, I., Andry, C., Siroky, M. B., Krane, R. J., et al. (1997). Vasculogenic female sexual dysfunction: The hemodynamic basis for vaginal engorgement insufficiency and clitoral erectile insufficiency. International Journal of Impotence Research, 9, 27–38.CrossRefGoogle Scholar
  41. Payer, L. (1992). Disease-mongers: How doctors, drug companies, and insurers are making you feel sick. New York: Wiley.Google Scholar
  42. Popper, K. R. (1959). The logic of scientific discovery. London: Routledge.Google Scholar
  43. Shifren, J. L., et al. (2008). Sexual problems and distress in United States women: Prevalence and correlates. Obstetrics & Gynecology, 112, 970–978.CrossRefGoogle Scholar
  44. Simon, J., et al. (2005). Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. The Journal of Clinical Endocrinology & Metabolism, 90, 5226–5233.CrossRefGoogle Scholar
  45. Sismondo, S. (2008). How pharmaceutical industry funding affects trial outcomes: Causal structures and responses. Social Science & Medicine, 66(9), 1909–1914.CrossRefGoogle Scholar
  46. Sismondo, S., & Doucet, M. (2010). Publication ethics and the ghost management of medical publications. Bioethics, 24(6), 273–283.CrossRefGoogle Scholar
  47. Stegenga, J. (2015). Measuring effectiveness. Studies in History and Philosophy of Biological and Biomedical Sciences., 54, 62–71.CrossRefGoogle Scholar
  48. Tavernise, S (2016) ‘Female Viagra’ Only Modestly increase sexual satisfaction, study finds. The New York Times. February 29.Google Scholar
  49. Thorp, J., Simon, J., Dattani, D., & et al. DAISY Trial Investigators. (2012). Treatment of hypoactive sexual desire disorder in premenopausal women: Efficacy of flibanserin in the DAISY study. Journal of Sexual Medicine, 9(3), 793–804.CrossRefGoogle Scholar
  50. Tiefer, L. (2006). Female sexual dysfunction: A case study of disease mongering and activist resistance. PLoS Medicine, 3, e178.CrossRefGoogle Scholar
  51. Wilholt, T. (2006). Design rules: Industrial research and epistemic merit. Philosophy of Science, 73(1), 66–89.CrossRefGoogle Scholar
  52. Woloshin, S., Schwartz, L. M., Frankel, B., & Faerber, A. (2014). US food and drug administration and design of drug approval studies. JAMA, 312, 2163–2165.CrossRefGoogle Scholar
  53. Woloshin, S., & Schwartz, L. M. (2016). US food and drug administration approval of flibanserin: Even the score does not add up. JAMA Internal Medicine, 176, 439–442.CrossRefGoogle Scholar
  54. Young, N., Ioannidis, J., & Al-Ubaydli, O. (2008). Why current publication practices may distort science. PLoS Medicine, 5(10), e201.  https://doi.org/10.1371/journal.pmed.0050201.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Leibniz University HannoverHannoverGermany
  2. 2.Bielefeld UniversityBielefeldGermany

Personalised recommendations